Brammer Bio, the best-in-class cell and gene therapy contract development and manufacturing organization, is proud to announce plans to build-out a 50,000 sq. ft. facility dedicated to late phase development, including Phase III and commercial production of viral vector-based and cell-based advanced therapies. The facility will be qualified and operational by Q2 of 2017 in Lexington, MA.
